The Improvement of Cardiac and Endothelial Functions of Xue-Fu-Zhu-Yu Decoction for Patients with Acute Coronary Syndrome: A Meta-Analysis of Randomized Controlled Trials

Table 1

Characteristics of the included studies.

Study ID	Sample size (T/C)	Type of disease	Age (T/C)	Baseline	Interventions		Duration	Outcome measures
					Treatment group	Control group
Lu (2020) [21]	43/40	UA	62.57 ± 8.42/63.39 ± 8.90	C	XFZYD + amiodarone	Amiodarone	4w	①②⑪
Zu (2020) [20]	38/38	AMI + PCI	59.68 ± 8.46/60.16 ± 8.26	C	XFZYD + RT	RT	8w	①②
Li (2019) [23]	46/45	STEMI + PCI	59.03 ± 3.62/58.19 ± 3.86	C	XFZYD + RT	RT	1w	①②③⑨⑩⑫
Wen (2019) [22]	52/52	AMI + PCI	60.30 ± 4.85/60.25 ± 4.87	C	XFZYD + RT	RT	4w	①⑨⑩⑫
Liu and Liu (2018) [24]	40/40	UA	NA/NA	C	XFZYD + RT	RT	4w	⑭
Li (2017) [26]	30/30	UA	57.9 ± 8.3/58.2 ± 8.5	C	XFZYD + RT	RT	2w	⑥⑦⑫⑬⑭
Wang (2017) [25]	53/53	AMI + PCI	57.36 ± 8.24/59.02 ± 9.78	C	XFZYD + RT	RT	2w	①②③④⑤⑨⑩⑫
Wang (2016) [27]	34/34	UA	NA/NA	C	XFZYD + RT	RT	8w	④⑤
Liu et al. (2013) [28]	30/30	AMI	NA/NA	C	XFZYD + RT	RT	2w	⑪
Zhang et al. (2012) [29]	30/30	AMI	61 ± 7/59 ± 8	C	XFZYD + RT	RT	2w	⑤
Jiang (2011) [30]	40/40	UA	NA/NA	C	XFZYD + RT	RT	4w	⑧
Guo (2009) [32]	25/24	UA	NA/NA	C	XFZYD + RT	RT	2w	⑧⑪
Zheng and Wang (2009) [31]	30/30	UA	64.8 ± 7.9/65.2 ± 7.4	C	XFZYD + RT	RT	8w	④⑤⑥⑦
Chen et al. (2008) [33]	42/42	USTEMI + UA	62.83 ± 10.14/64.83 ± 10.75	C	XFZYD + RT	RT	8w	⑧
Wang et al. (2006) [34]	32/18	UA	65.4 ± 7.6/65.3 ± 7.8	C	XFZYD + RT	RT	8w	④⑤⑥⑦
Tang et al. (2004) [35]	30/30	AMI	NA/NA	C	XFZYD + RT	RT	12w	①②③

① LVEF; ② LVEDD; ③ LVESD; ④ NO; ⑤ ET-1; ⑥ ICAM-1; ⑦ VCAM-1; ⑧ CRP; ⑨ SOD; ⑩ MDA; ⑪ BNP; ⑫ CK-MB; ⑬ cTnI; ⑭ ADRs. The numerical values of age are presented as mean value ± standard deviation in the treatment group (T) and the control group (C). Abbreviations: ADRs, adverse drug reactions; AMI, actue myocardial infarction; BNP, brain natriuretic peptide; C, consistent; CK-MB, creatine kinase-MB; CRP, C-reactive protein; cTnI, cardiac troponin I; ET-1, endothelin-1; ICAM-1, intercellular adhesion molecule-1; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; MDA, malondialdehyde; NA, not available; NO, nitric oxide; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; RT, routine treatment; SOD, superoxide dismutase; STEMI, ST-segment elevation myocardial infarction; T/C, treatment group/control group; UA, unstable angina; VCAM-1, vascular cell adhesion molecule-1; w, week; XFZYD, Xue-Fu-Zhu-Yu decoction.